A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients

Journal of Heart and Lung Transplantation

Volumn 21, Issue 9, 2002, Pages 1016-1021

  Balram, C ^a   Sivathasan, C ^b   Cheung, Yin Bun ^a   Tan, Say Beng ^a   Tan, Yong Seng ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; PREDICTION; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MODELS, THEORETICAL; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 0036754192     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00419-9     Document Type: Article

References (29)

1. Moris P.J. Cyclosporine A. Transplantation. 32:1981;349.
2. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205-218.
3. Schroeder T.J., Hariharan S., First M.R. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc. 27:1995;837-839.
4. Kahan B.D. High variability of drug exposure a biopharmaceutic risk factor for chronic rejection. Transplant Proc. 30:1998;1639-1641.
5. Friman S., Backman L. A new microemulsion formulation of cyclosporine pharmacokinetic and clinical features. Clin Pharmacokinet. 30:1996;181-193.
6. Holt D.W., Mueller E.A., Kovarik J.M., van Bree J.B., Kutz K. The pharmacokinetics of Sandimmun Neoral a new oral formulation of cyclosporin. Transplant Proc. 26:1994;2935-2939.
7. Keown P., Kahan B.D., Johnston A., et al. Optimisation of cyclosporine therapy with new therapeutic drug monitoring strategies report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc. 30:1998;1645-1649.
8. Jennison S.H., Wesp A.G., McBride L.R., Miller L.W. Limited utility of early trough cyclosporine level monitoring to predict the rate of acute rejection in the first 3 months after cardiac transplantation. Transplant Proc. 26:1994;2732-2735.
9. Amante A.J., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc. 28:1996;2162-2163.
10. Grevel J., Kahan B.D. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem. 37:1991;1905-1908.
11. Kahan B.D., Welsh M., Rutzky L.P. Challenges in cyclosporine therapy the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit. 17:1995;621-624.
12. Keown P., Landsberg D., Halloran P., et al. A randomised, prospective multicentre pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Transplantation Study group. Transplantation. 62:1996;1744-1752.
13. Cockroft D.W., Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31.
14. Fisher L.D., van Belle G. Biostatistics a methodology for the health sciences. 1993;692 Wiley, New York.
15. Sheiner L.B., Tozer T.N. Clinical pharmacokinetics the use of plasma concentrations of drugs. Melmon K.L., Morelli H.F., Clinical pharmacology basic principles of therapeutics. 1978;71 Macmillan, New York.
16. Holford N.H.G. The target concentration approach to clinical drug development. Clin Pharmacokinet. 29:1995;287-291.
17. Pai S.Y., Fruman D.A., Leong T., et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporin A. Blood. 84:1994;3974-3979.
18. Batiuk T.D., Pazderka F., Halloran P.F. Cyclosporin treated renal transplant patients have only partial inhibition of calcineurin phosphatase activity. Transplant Proc. 27:1995;840-841.
19. Halloran P.F., Helms L.M., Kung L., Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 68:1999;1356-1361.
20. Kahan B.D., Kramer W.G., Williams C., Wideman C.A. Applications of Bayesian forecasting to predict appropriate cyclosporine dosage regimens for renal allograft patients. Transplant Proc. 18:(suppl 5):1986;200-203.
21. Anderson J.E., Munday A.S., Kelman A.W., et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther Drug Monit. 16:1994;160-165.
22. Johnston A., Sketris I., Marsden J.T., et al. A limited sampling strategy for the measurement of cyclosporin AUC. Transplant Proc. 22:1990;1345-1346.
23. Amante J., Kahan B.D. Abbreviated area-under-the-curve strategy for monitoring cyclosporin microemulsion therapy in immediate posttransplant period. Clin Chem. 42:1996;1294-1296.
24. Grevel J., Napoli K.L., Welsh M.S., Atkinson N.E., Kahan B.D. Prediction of acute graft rejection in renal transplantation the utility of cyclosporin blood concentrations. Pharm Res. 8:1991;278-281.
25. Lindholm A., Welsh M., Rutzky L., Kahan B.D. The adverse impact of high cyclosporin clearance rates on the incidence of acute rejection and graft loss. Transplantation. 55:1993;985-993.
26. Schroeder T.J., Hariharan S., First M.R. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc. 26:1994;2787-2790.
27. Johnston A., David O.J., Cooney G.F. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc. 32:(suppl 3A):2000;S53-S56.
28. Cooney G.F., Jeevanandam V., Choudhury S., Feutren G., Mueller E.A., Eisen H.J. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over one year. Transplant Proc. 30:1998;1892-1894.
29. Cantarovich M., Elstein E., de Varennes B., Barkun J.S. Clinical benefit of Neoral dose monitoring with cyclosporine 2 hour post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 68:1999;1839-1842.